Bioanalytical Systems, Inc. (NASDAQ:BASI)
today announced financial results for the first quarter ended December 31, 2012.
Revenue decreased to $5,803,000, compared to $7,516,000 for the first quarter of fiscal 2012. Gross margin improved to 32.0% of revenue, compared to 19.7% a year ago. Operating income for this year’s first quarter increased to $302,000, versus an operating loss of $1,302,000 for the same period last year, driven by the increase in gross margin and a 44.2% reduction in operating expenses. Net income for the first quarter of fiscal 2013 was $139,000, or $0.02 per basic and diluted share. This compares to a net loss for the first quarter of fiscal 2012 of $1,491,000, or $0.21 per basic and diluted share.
EBITDA for this year’s first quarter was $851,000, versus an EBITDA loss of $704,000 for the first quarter of fiscal 2012. Cash provided by operations was $702,000 for the first quarter of the current fiscal year, versus $590,000 a year ago.
President & CEO and CFO Jacqueline Lemke said, "With the notable exception of revenue, all of our operating metrics moved decisively in the right direction in the first quarter compared to prior year. We believe these improvements are sustainable. Now we are implementing a strategy to restore revenue growth that builds on BASi’s competitive strengths - specialty assay and discovery capabilities, a long history of regulatory excellence, and our market-changing Culex NxT system. While it will take time for these initiatives to translate into higher sales for BASi, we expect to begin seeing positive results later this fiscal year.
"As we anticipated, our first quarter service revenue comparison was negatively affected by the consolidation of our Oregon laboratory into our West Lafayette facility and the closure of our UK lab in last year’s second half. Service revenue in the current quarter was also impacted by unexpected delays in the start of certain pharmaceutical analysis contracts. Although product sales have historically been strongest in the first quarter of the fiscal year, it appears that customers delayed orders in anticipation of the launch of our new advanced Culex® NxT
sampling system. Supporting this view, product orders have picked up in the past few weeks, which is an encouraging sign for the future.
"On the service side, we recently announced the first of a number of collaborative research projects and preferred provider partnerships that we expect to contribute to revenue beginning this fiscal year. Additionally, we currently are interviewing to hire both a West Coast and an East Coast bioanalytical services sales representative to improve our reach across the United States, and have realigned sales compensation to incentivize new sales and reward winning business based upon referrals and reputation. We remain optimistic about the outlook for fiscal 2013.”